Specific cytotoxic T lymphocytes (CTL) reacting to the VEGFR2-169 peptide were induced in 11 (61%) of the 18 evaluable patients. The disease control rate was 67%, and the median overall survival time was 8.7 months.
Immune response to the peptide vaccine showed prolonged survival compared to nonresponders. K-ras-specific T cells were selectively accumulated in the tumor.
This vaccine is safe, can induce specific immune responses, and it appears to have a positive outcome in overall survival. The five pancreatic cancer patients have shown a mean disease-free survival (DFS) of 35.2+ months and a mean overall survival (OS) of 44.4+ months.
1 with liver metastasis of PC refractory to gemcitabine
Case report
The patient initially underwent partial remission of liver metastasis which proceeded after 6 months into a complete remission with duration of 8 months.